Načítá se...
Transient asymptomatic pulmonary opacities occurring during osimertinib treatment
INTRODUCTION: Osimertinib is an Epidermal Growth Factor Receptor (EGFR) Inhibitor licensed for the treatment of EGFR mutant, T790M positive, non-small cell lung cancer (NSCLC). Previously unreported, common, transient asymptomatic pulmonary opacities (TAPOs) were noted at the University of Colorado...
Uloženo v:
| Vydáno v: | J Thorac Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5353353/ https://ncbi.nlm.nih.gov/pubmed/27618759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2016.08.144 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|